Vaccines

31 Jul 2021 I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
30 Jul 2021 Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
30 Jul 2021 AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021
28 Jul 2021 Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
28 Jul 2021 Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose
23 Jul 2021 EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union
23 Jul 2021 Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern
21 Jul 2021 EMA starts rolling review of COVID-19 vaccine Vidprevtyn
20 Jul 2021 OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
20 Jul 2021 Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose
20 Jul 2021 U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine
17 Jul 2021 Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
13 Jul 2021 Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma
13 Jul 2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
13 Jul 2021 ReiThera Announces Preliminary Phase 2 Data from its COVID-19 Vaccine Candidate
09 Jul 2021 Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate
08 Jul 2021 Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor
07 Jul 2021 Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
07 Jul 2021 Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
04 Jul 2021 Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
02 Jul 2021 Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
02 Jul 2021 HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine
01 Jul 2021 Zydus applies to the DCGI for EUA to launch ZyCoV-D, the world’s first Plasmid DNA vaccine for COVID-19
01 Jul 2021 Intranasal COVID-19 vaccine demonstrates single-dose efficacy in preclinical studies, in parallel with achievement of Phase 1 clinical milestone
01 Jul 2021 Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top